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Abstract 
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) 
are aggressive, poorly differentiated brain tumors with limited effective therapies. Using 
Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic drivers of 
medulloblastoma and CNS-PNET. Cross-species gene expression analyses classified SB-driven 
tumors into distinct medulloblastoma and CNS-PNET subgroups, indicating they resemble 
human SHH and group 3 and 4 medulloblastoma and CNS neuroblastoma with FOXR2 
activation. This represents the first genetically-induced mouse model of CNS-PNET and a rare 
model of group 3 and 4 medulloblastoma. We identified several putative proto-oncogenes 
including Arhgap36, Megf10, and Foxr2. Genetic manipulation of these genes demonstrated a 
robust impact on tumorigenesis in vitro and in vivo. We also determined that FOXR2 interacts 
with N-MYC, increases C-MYC protein stability, and activates FAK/SRC signaling. Altogether, 
our study identified several promising therapeutic targets in medulloblastoma and CNS-PNET. 
 
Significance 
A transposon-induced mouse model identifies several novel genetic drivers and potential 
therapeutic targets in medulloblastoma and CNS-PNET. 
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Introduction 
Embryonal tumors, including medulloblastoma and central nervous system primitive 
neuroectodermal tumors (CNS-PNETs), represent the most common malignant pediatric brain 
tumors (1). For ease of historical comparison, CNS-PNET is used in this manuscript according to 
the 2007 World Health Organization CNS tumor classification and includes CNS 
neuroblastomas, CNS ganglioneuroblastomas, medulloepitheliomas, and ependymoblastomas, 
although CNS-PNET no longer exists as an umbrella term(2). Medulloblastoma and CNS-PNET 
have similar histology: densely-packed, small cells with hyperchromatic nuclei and little 
cytoplasm. Medulloblastomas are usually cerebellar, while CNS-PNETs occur predominantly in 
the cerebrum. Aggressive, multi-modality treatments improve survival but produce lifelong side 
effects, and 5-year survival rates remain 60-65% for medulloblastoma and 20-40% for CNS-
PNET(3).  
 Medulloblastoma and CNS-PNET are molecularly heterogenous. Medulloblastoma 
includes four molecular subgroups: WNT, SHH, group 3, and group 4; WNT and SHH are 
associated with mutations activating those pathways, but groups 3 and 4 remain less defined(4). 
A genomic study by Picard et al. identified three distinct CNS-PNET subgroups: primitive-
neural, oligo-neural, and mesenchymal(5). Using methylation and gene expression-based 
analyses, Sturm et al. identified 4 molecular subgroups of CNS-PNET associated with gene 
fusions(6). While our understanding of the tumor biology has improved, a lack of animal models 
and targetable oncogenic drivers impede therapeutic development, particularly in group 3/4 
medulloblastoma and CNS-PNET.  
 We used Sleeping Beauty (SB) transposon mutagenesis to identify novel medulloblastoma 
and CNS-PNET drivers. Transposition initiated in neural progenitor cells using Nestin-Cre was 
used alone, with Trp53
lsl-R270H/+
,
 
or with Pten-deficiency to generate medulloblastomas and CNS-
PNETs. These tumors resembled human medulloblastoma and CNS-PNET histologically and 
transcriptionally. Three candidate oncogenes, Arhgap36, Foxr2, and Megf10 were validated in 
vitro and in vivo and their mechanisms examined.  
 
Materials and Methods 
 
Generation of transgenic mice 
 Animal studies were conducted using procedures approved and 
monitored by the Institutional Animal Care and Use Committee at the University of Minnesota 
(UofMN). Nestin-Cre mice(7) were bred to either T2/Onc (chromosome 1/15)(8) or T2/Onc2 
(chromosome 4)(9) to generate Nestin-Cre:T2/Onc(2). Rosa26
lsl-SB11/+
(10) were bred to either 
Trp53
lsl-R270H/+
(11) or Pten
flox/flox
(12) to generate Rosa26
lsl-SB11/+
:Pten
flox/flox 
or Rosa26
lsl-
SB11/+
:Trp53
lsl-R270H/+
. Nestin-Cre:T2/Onc(2) mice were bred to Rosa26
lsl-SB11/+
:Pten
flox/flox
 or 
Rosa26
lsl-SB11/+
:Trp53
lsl-R270H/+
 to generate mice with and without CNS-restricted SB-mutagenesis 
on wildtype (WT), Trp53
lsl-R270H/+
, and Pten
flox/+ 
backgrounds. T2/Onc(2) excision PCR was 
performed as described with primers in Supplementary Table 1(8).  
 
Immunohistochemistry (IHC), immunoprecipitation (IP), and western blotting 
Unstained tissue microarray (TMA) sections of formalin-fixed, paraffin-embedded (FFPE) 
human tumor specimens were obtained through the UofMN Materials Procurement Network (11 
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samples) and Johns Hopkins University (54 samples). FFPE tissue slides were stained with 
Hematoxylin and Eosin (H&E) or IHC using standard methods. IPs were done (Active Motif 
#54001) with 500g total protein. Western blotting was done with whole cell lysates as 
described(13) using antibodies in Supplementary Table 2.   
 
DNA-Common insertion site (D-CIS) analysis 
Linker-mediated PCR to identify transposon insertion sites was performed as described(13). 
Transposon insertion sites were annotated using TAPDANCE(14). Non-redundant insertion sites 
representing >0.1% of the mapped insertions from each tumor library were used to generate CIS 
(P-value <0.05). 
 
Transcriptional profiling 
Isolated tumor RNA (Qiagen #75114) was assessed for quality using capillary electrophoresis 
(RIN>6.5, Agilent 2100 BioAnalyzer). Paired-end sequencing (30-40 million reads/sample) of 
TruSeq-prepared libraries was performed (Illumina HiSeq 2000). Raw FASTQ files are available 
at the NCBI Sequence Read Archive and linked to Gene Expression Omnibus SuperSeries 
(GSE122050).  FASTQ files were mapped to the MM10 genome (T2/Onc and Rosa26
lsl-SB11/+
 as 
additional chromosomes)(15) using STAR-Fusion (https://github.com/STAR-Fusion/STAR-
Fusion/wiki). Transcript FPKM values were computed using cuffquant and cuffnorm and 
adjusted by +0.1(16).  
 
T2/Onc fusion identification 
To identify T2/Onc:genome fusions, we analyzed the chimeric.out.junction and chimeric.out.sam 
output files from STAR-Fusion to summarize the number of junction (one read contains the 
T2/Onc:genome junction) and bridge (one paired-end read maps to T2/Onc and the other to the 
genome) reads present within 1000bp regions. Fusions supported by ≥1 junction read or ≥3 
bridging reads were retained for analysis. Manual detection of T2/Onc(2):Arhgap36 transcripts 
was done using 500ng of purified RNA (Invitrogen #15596-018), reverse-transcribed (Invitrogen 
#18080-051) and amplified using primers in Supplementary Table 1.  
 
Gene cluster similarity (GC-SIM) 
GC-SIM was used for unsupervised, unbiased identification of similar gene clusters across 
transcriptional datasets. Transcriptional profile datasets were individually log-transformed, 
mean-centered, filtered for highly variant genes, and hierarchically clustered using average 
linkage and (1 – Pearson correlation) as the distance metric.  Gene clusters with node correlation 
and size >respective thresholds were retained. Cross-dataset cluster pairs were tested for 
enrichment of common gene members (Fisher’s Exact Test) to identify conserved transcriptional 
patterns. 
 
RT-PCR and 5-rapid amplification of cDNA ends (5’-RACE) 
For CNS-PNET expression analysis, cDNAs were synthesized (Applied Biosystems #4368814) 
and qRT-PCR was performed (Invitrogen #4369016). For Shh activation assays, purified 
cellular RNA (Ambion #12183025) was reverse transcribed (Invitrogen #11755050) and qRT-
PCR was done in triplicate (Roche #4673492001). Shh activation was done as described(17). For 
5’-RACE (Ambion #AM1700), tumor RNA was extracted from human medulloblastomas 
(Invitrogen #15596-018) and normal human brain RNA was purchased from BioChain 
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(R1244039-50, R1244035-50, R1234040-10). Subsequent detection of transcripts by RT-PCR 
was performed with 500ng RNA (Invitrogen #18080-051). Primers and probes are listed in 
Supplementary Table 1.  
 
Cell culture/assays 
Cell lines were maintained, authenticated, and tested for mycoplasma as described in 
Supplementary Table 3. MTS (Promega G1111), soft agar assays, and transfections were done as 
described(13). Stable lines transfected with cDNAs (ARHGAP36 (Q6ZRI8-5), FOXR2 (Q6PJQ5-
1), Megf10 (Q6DIB5-1)) were cultured as polyclonal populations in puromycin. Transient 
transfection in HEK293Ts was done per manufacture’s protocol (Invitrogen 11668019). 
CRISPR-KO clones were isolated as described(13). Briefly, Daoy cells were transfected with 
PiggyBAC transposase and a puromycin-selectable PiggyBAC transposon vector containing 2 
FOXR2 guide RNAs (sequences in Supplementary Table 1) and Cas9. Isolated clones were 
sequenced to identify changes in FOXR2. Wound healing assays were performed as 
described(18). Primary granule neuron precursors (GNPs) were isolated from neonatal C57BL/6J 
and thymidine incorporation assays were performed as described(19). 
 
in vivo assays 
NRG mice (Jackson 007799) were injected as described(20). Briefly, C17.2 cells were prepared 
in HBSS, counted, and stored on ice prior to injection (2x10
5
 cells/2l injection). P0 mice were 
injected in the fourth ventricle (stereotactic coordinates: 1.5mm anterior to Bregma, 1.5mm 
deep). Successful injection was verified on P1 by luciferase imaging as described(20). Adult 
intracranial injections were performed as described(19). Female NU/J mice (Jackson 002019, 6-8 
weeks old) were anesthetized (81 mg/kg ketamine, 13.8 mg/kg xylazine) and injected with 1x10
6
 
cells/5l (prepared as above). For flank tumor assays, female NU/J mice (Jackson 002019, 6-8 
weeks old) were injected with 1x10
6
 C17.2 cells (prepared as above) resuspended 1:1 in HBSS 
and Matrigel (Corning CB-#40234C). Tumor volume = (l x w
2
)/2, l=length and w=width. 
 
Results 
 
SB Mutagenesis Promotes Medulloblastoma and CNS-PNET Formation 
To identify genetic drivers of medulloblastoma and CNS-PNET, we targeted Nestin+ 
neural and glial precursor cells with SB-mutagenesis on three genetic backgrounds: wildtype 
(WT), Pten heterozygous (Pten
flox/+
), or Trp53 mutant (Trp53
lsl-R270H/+
). Pten
flox/+ 
and Trp53
lsl-
R270H/+
 served as sensitizing backgrounds as they are mutated in human medulloblastoma and 
CNS-PNET(21,22). IHC revealed SB expression throughout the developing brain, including 
cells within the granule layer, white matter, surrounding the fourth ventricle, subependymal 
midbrain, subventricular zone, and olfactory bulb (Supplementary Fig. S1A-G). Experimental 
cohorts harbored one of three transposon concatemers (Supplementary Fig. S1H). SB-
mutagenesis significantly reduced survival in combination with Trp53
lsl-R270H
 (Supplementary 
Fig. S1I-K).  Upon necropsy we observed masses in the brain, testicles, bone, peripheral lymph 
nodes, and spleen (Supplementary Fig. S1I-K, Supplementary Table 4).  
Histological analysis of brain masses revealed the presence of infratentorial 
medulloblastoma and supratentorial CNS-PNET (22 medulloblastomas and 14 CNS-PNETs) 
with highest medulloblastoma frequency in Trp53
lsl-R270H/+
 mice (Fig. 1A-B). The high-copy 
transposon (T2Onc2, chromosome 4) produced the highest proportion of medulloblastoma, while 
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CNS-PNETs were equally derived from chromosome 4 and 15 concatemers (Supplementary Fig. 
S2A). Tumors expressed nuclear SB by IHC and showed transposon mobilization by PCR 
(Supplementary Fig. S2B-C). 
 
SB-Induced Medulloblastoma and CNS-PNET Resemble Human Tumors Histologically 
SB-induced medulloblastomas originated in the cerebellum whereas CNS-PNETs 
occurred in the rostral portion of the brain, overwhelming the olfactory bulbs, lateral ventricle, 
and cortex (Fig. 1A, C-D). Both tumor types resembled their human counterparts histologically 
(small round cells with high nuclear:cytoplasmic ratios, Homer-Wright rosettes, vascularization, 
and mitotic figures), expressed diagnostic markers for human medulloblastoma and CNS-PNET 
(Synaptophysin, Ki67, and Nestin), and stained negatively for the astrocytic marker Gfap (Fig. 
1C-D). 50% of medulloblastomas and 100% of CNS-PNETs exhibited metastatic characteristics, 
including infiltration into the leptomeninges, parenchyma, brainstem, and cortex (Supplementary 
Table 4). Leptomeningeal spread is of interest due to its associated poor prognosis, prevalence 
(one-third of patients), and difficulty modeling(5,23). 
 
SB-Induced Medulloblastomas Resemble Non-WNT Human Medulloblastoma  
We transcriptionally profiled 18 SB-induced medulloblastomas, revealing two clear 
subgroups that each matched human medulloblastoma subtypes (Fig. 2A)(6). The first subgroup 
(N=13) showed increased Gli1, canonically associated with human SHH medulloblastoma(24). 
The second subgroup (N=5) showed increased Npr3 and Kcna1, markers for human group 3 and 
4, respectively(24). More globally, the Gli1-overexpressing medulloblastoma gene set 
overlapped with highly-expressed genes in human SHH medulloblastoma (N=48, Fig. 2A, 
Supplementary Table 5)(6). Similarly, the Npr3 and Kcna1-overexpressing mouse gene set 
overlapped with highly-expressed genes in human group 3 and 4 medulloblastoma (N=120). 
Mouse tumors did not exhibit Wnt signatures. 
 
 SB-Induced CNS-PNETs Resemble Human CNS Neuroblastoma with FOXR2 Activation (CNS 
NB-FOXR2) 
Transcriptional profiling comparing mouse CNS-PNETs (N=5) to published human 
CNS-PNETs (N=58) revealed two subgroups (Fig. 2B)(6). A single cluster of co-varying genes 
(N=298) was significantly enriched in both human and mouse CNS-PNET and contained high 
levels of CNS NB-FOXR2 associated genes, including MMP24, KCJN9, and CHGB (Fig. 2B, 
Supplementary Table 6). Consistent with CNS NB-FOXR2 classification, SB-induced CNS-
PNETs showed significantly increased Olig1, Olig2, and Sox10 by qPCR and were Olig2+ by 
IHC (Supplementary Fig. 2D-E). The three remaining mouse CNS-PNETs had elevated 
expression of CNS EFT-CIC marker genes (Shc4, Argdib, and Pole) but no clearly 
corresponding human subgroup. 
 
CIS reveal candidate cancer genes 
We performed linker-mediated PCR on 22 medulloblastomas and 13 CNS-PNETs and 
identified 390,000 and 155,000 non-redundant insertions, respectively. TAPDANCE 
analysis(14) identified 13 medulloblastoma and 15 CNS-PNET DNA-CIS (D-CIS)(Fig. 3A, 
Supplementary Table 7). We also identified RNA-CIS (R-CIS) in both tumor types, defined as 
transposon fusion transcripts present in both 10% of cases and 1 tumor (Fig. 3A, 
Supplementary Table 7). For several putative oncogenes, the presence of a T2/Onc(2) fusion 
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transcript significantly increased expression (Fig. 3B). We identified genes previously implicated 
in medulloblastoma, including Gli1 and Pten; upregulation of GLI1 expression and PI3K 
pathway activation through PTEN loss are observed in human medulloblastoma(21). Predicted 
transposon-mediated driving effects on Gli1 expression were confirmed by IHC (Supplementary 
Fig. S3A). We also confirmed Pten reduction and a corresponding increase in pAkt with Pten 
insertions (Supplementary Fig. 3B). Arhgap36 was most frequently modified, with insertions 
identified in 14 (D-CIS) and 13 (R-CIS) medulloblastomas and 2 CNS-PNETs (R-CIS). Enox2, a 
tumor-associated NADH oxidase involved in the growth of several cancer cell lines(25), was 
also a D and R-CIS in medulloblastoma (predicted SB oncogene).  
We identified known and novel molecular changes in SB-induced CNS-PNETs. Pten was 
a predicted tumor suppressor gene (TSG) and loss of PTEN through 10q loss or mutation is 
observed in human CNS-PNET(22). Novel to this study, NF1 was the most targeted CNS-PNET 
TSG. We identified several other predicted Ras effector gene alterations, including Eras 
overexpression and Erbb2ip and Rasa3 disruption (Supplementary Table 4). Tumors harboring 
these insertions exhibited increased pErk (Supplementary Fig. S3C, Supplementary Table 4) 
supporting Ras pathway activation. We also observed NF1 locus deletion in a subset of human 
CNS-PNETs (Supplementary Fig. S3D).  
We next analyzed our CIS gene expression in published human medulloblastomas and 
CNS-PNETs (Fig. 3C-E)(6). GRIA4 showed high expression in both SHH medulloblastoma and 
CNS NB-FOXR2. FOXR2 is elevated in a subset of WNT medulloblastoma and CNS NB-
FOXR2. Interestingly, ARHGAP36 is highly expressed in group 3 and 4 medulloblastoma, with 
low expression in SHH (Supplementary Fig. S4A), while in the mouse Arhgap36 insertions 
occurred in Shh and group 3/4 tumors (7/12 Shh and 4/5 group 3/4 tumors, Supplementary Table 
4).  
 
ARHGAP36 Expression is Associated with Poor Prognosis in Human Medulloblastoma 
Transposon location and orientation implicate Arhgap36 as an oncogene, with insertions 
upstream of the locus or within intron 1 and significantly increasing gene expression (Fig. 4A-
B). T2/Onc:Arhgap36 transcripts displayed precise fusion of the T2/Onc splice donor to the 
Arhgap36 exon 2 splice acceptor (Supplementary Fig. S4B), generating a 15 amino acid N-
terminal truncation with translation from an in-frame ATG. Tumors with Arhgap36 insertions 
showed high levels of cytoplasmic Arhgap36 by IHC compared to tumors without Arhgap36 
insertions, which displayed sparse nuclear expression similar to normal granule cells (Fig. 4C). 
Spatial and temporal analysis of ARHGAP36 expression in normal human and mouse cells 
within developing and mature cerebella showed nuclear localization throughout the molecular 
layer (ML), Purkinje cell layer (PC) and internal granule cell layer (IGL)(Supplementary Fig. 
S4C). In two combined TMAs of human medulloblastoma, 37/65 (56%) and 8/65 (12%) 
expressed cytoplasmic and nuclear ARHGAP36 expression, respectively, by IHC (Fig. 4D). 
ARHGAP36 protein was expressed across all human subgroups, although increased ARHGAP36 
transcript was only expressed in group 3/4 human medulloblastoma (Fig. 4E, Supplementary Fig. 
S4A)(24). Overall and cytoplasmic ARHGAP36 expression correlated with accelerated mortality 
(Fig. 4F, Supplementary Fig. S4D). 
We further investigated ARHGAP36 transcript profiles using 5-RACE on human group 
3/4 medulloblastoma samples, cell lines, and normal cerebellar cells. Several ARHGAP36 
amplification products were identified (Supplementary Fig. 4E-F) predicting expression of 
canonical isoform 1(*), 5(**), and 3(***; ****). All 3 isoforms contain intact ARHGAP36 
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predicted functional domains, including an arginine-rich domain (ARR), nuclear localization 
sequence (NLS), and GTPase-activating protein (GAP) domain. Interestingly, the 5’ ends of *** 
and **** begin with intron 2 sequences splicing to exon 3 and an in-frame ATG located in exon 
4. Target-specific RT-PCR revealed these ARHGAP36 sequences in additional tumor samples, 
while normal fetal cerebellum only expressed isoform 1 (Supplementary Fig. S4G). 
 
ARHGAP36 Promotes Tumor Formation in Neural Progenitor Cells 
To further characterize the role of ARHGAP36 in medulloblastoma, we overexpressed 
truncated ARHGAP36 (isoform 5) in the mouse neural progenitor cell line C17.2 (Supplementary 
Fig. 5A)(26). Increased ARHGAP36 significantly enhanced soft agar colony formation but did 
not affect proliferation or collective cell migration rate (Fig. 5A, Supplementary Fig. S5B-C). 
C17.2 cells expressing ARHGAP36 formed tumors significantly faster in the flanks of NU/J 
mice than luciferase control cells (Fig. 5B). When injected orthotopically into adult NU/J mice, 
C17.2 cells localized to the granule layer of the cerebellum where ARHGAP36 expression drove 
leptomeningeal spread into the cerebrum and cerebellar tumor formation, reducing median 
survival from 99 to 71 days (Fig. 5C-D). Additionally, increased ARHGAP36 expression in 
primary GNPs significantly increased their proliferation (Fig. 5E). As previously reported, 
ARHGAP36 strongly activated Shh signaling in C17.2 cells in a ligand-independent manner, 
providing a potential mechanism for ARHGAP36-driven tumorigenesis (Fig. 5F)(17,27). 
Additionally, SB transposon insertions in the Arhgap36 locus were mutually exclusive with 
insertions in Gli1 and Gli2, Shh pathway activators (Fig. 5F).  
 
Megf10 Promotes Transformation in vitro and in vivo 
Megf10 (predicted SB oncogene) was identified as an R-CIS, with fusion transcripts in 3 
medulloblastomas significantly increasing expression (Fig. 3A-B). Megf10 is expressed 
throughout the developing CNS and is a positive regulator of Notch signaling(28). MEGF10 is 
upregulated in a subset of human CNS-PNET and medulloblastoma (15/26 medulloblastomas, 
14/58 CNS-PNETs, Supplementary Fig. S5D). Megf10 expression in C17.2 cells significantly 
enhanced colony formation in soft agar, proliferation by MTS, and flank tumor formation (Fig. 
5G-I). Additionally, increased Megf10 expression in GNPs increased their proliferation by 1.7-
fold, though not significantly possibly due to low sample size (Fig. 5E). Megf10 had no effect on 
C17.2 cell Notch signaling, however, by western blot (Supplementary Fig. S5E).  
 
FOXR2 Promotes Transformation in Human and Mouse Cells 
All Foxr2 transposon insertions were located upstream of the translation start site and 
drove increased Foxr2 expression, predicting an oncogenic role (Fig. 6A-B). The presence of a 
Foxr2 insertion significantly reduced median survival from 166.5 to 116.5 days (Supplementary 
Fig. S6A). FOXR2 overexpression in C17.2 cells significantly increased soft agar colony 
formation and collective cell migration without increasing proliferation (Fig. 6C-E, 
Supplementary Fig. S6B). C17.2 FOXR2 cells formed flank tumors significantly faster than 
C17.2 Luc controls (Fig. 6F). When injected orthotopically into adult NU/J mice, C17.2 FOXR2 
cells migrated to the granule layer of the cerebellum and formed large, vascular tumors, reducing 
median survival from 99 to 43 days (Supplementary Fig. 6C, Fig. 6G-H). C17.2 FOXR2 cells 
injected orthotopically into neonatal NRG mice also significantly reduced median survival 
compared to C17.2 Luc and resulted in tumor formation (110 vs 183 days, Fig. 6I). Importantly, 
FOXR2 overexpression drove increased proliferation in primary GNPs (Fig. 5E). Using the 
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CRISPR/Cas9 system, we knocked out (KO) FOXR2 in Daoy, a human medulloblastoma cell 
line. Daoy clone #21 had a nonsense mutation in exon 1 resulting in FOXR2 protein loss, 
decreased proliferation, and decreased soft agar colony formation, all rescued by FOXR2 cDNA 
expression (Fig. 6J-L).  
 
FOXR2 Has a Multi-Faceted Mechanism Including Effects on MYC and FAK 
FOXR2 has many suggested oncogenic mechanisms, including interaction with C-
MYC(29). We confirmed this interaction by CoIP in a human Schwann cell line, HSC1, and 
C17.2 cells stably expressing FOXR2 (Fig.7A, Supplementary Fig. 6D). To determine if FOXR2 
interacts with other forms of MYC, we transiently transfected HEK293T cells with V5-tagged C-
MYC, L-MYC and N-MYC. We observed reduced interaction of FOXR2 with N-MYC and 
minimal interaction with L-MYC (Fig. 7B). To determine if FOXR2 stabilizes C-MYC, we 
treated cells with cycloheximide (CHX) to inhibit translation. Almost all C-MYC protein was 
degraded in control HSC1 cells, but with FOXR2, C-MYC levels were only reduced by half 
after 3 hours, indicating FOXR2 is stabilizing (Fig. 7C). Interestingly, C-MYC was highly stable 
in C17.2 cells regardless of FOXR2 expression, likely due to their immortalization by V-
Myc(26), implying that FOXR2 transforms C17.2 cells through alternative mechanisms.  
To further characterize the oncogenic mechanism of FOXR2, we synthesized FOXR2 
cDNA constructs missing the following predicted domains: NLS(NLS)(30), MYC interaction 
(MYC)(29), low complexity regions (LC1, LC2 and LC1/2)(31), and forkhead box 
transcription factor (TF)(31)(Fig. 7D). We stably expressed each mutant and performed soft 
agar assays in C17.2 and HSC1 cells. Surprisingly, no single deletion mutant completely 
ablated the colony formation promoting capacity of FOXR2 in either line, but loss of the Myc 
interaction and LC2 domains significantly reduced colony formation (Fig. 7D, Supplementary 
Fig. 6E). C17.2 FOXR2MYC also had an intermediate phenotype in the flank (Fig. 6F). We 
verified that the FOXR2MYC mutant did not bind C-Myc (Supplementary Fig. 6F). Given no 
single domain loss completely ablated colony formation but some did reduce it, we conclude 
FOXR2 has a multi-faceted mechanism. We observed a slight change in the actin cytoskeleton of 
FOXR2-expressing cells, prompting assessment of focal adhesion kinase (FAK) activation. 
C17.2 cells expressing FOXR2 displayed increased Fak phosphorylation (Y397), resulting in 
increased (activating) phosphorylation at Src Y416 (Fig. 7E). This effect is Myc-independent 
(Supplementary Fig. 6G). Correspondingly, FOXR2 loss in Daoy cells resulted in decreased 
pFAK and pSRC rescuable by FOXR2 cDNA expression (Fig. 7E). 
 
Discussion 
We used SB transposon mutagenesis to identify novel drivers of medulloblastoma and 
CNS-PNET. Over half of our D-CIS and several of our R-CIS were reported in previous SB 
medulloblastoma screens(23,32-34), including Pten, Wac, Arid1b, Arhgap36, Foxr2, and 
Megf10, making them especially compelling candidates (Supplementary Table 8).  Notably, 
several R-CIS are located on chromosomes 4 and 15, the locations of the T2/Onc2 and T2/Onc 
concatemers, respectively. Although local hopping may account for bias toward genes on these 
chromosomes, several are implicated in cancer, including Tle1 and Ptprd (35,36). Additionally, 
these concatemers have been previously used to identify R-CIS in osteosarcoma, and only one R-
CIS gene was common to both studies (Cdkn2a, Supplementary Table 9)(15).  Our 
medulloblastoma R-CIS include several highly compelling targets, including Megf10. We 
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identified a novel, oncogenic role for Megf10 in neural progenitor cells, the mechanism for 
which warrants further study.  
Ours is the first transposon screen to produce CNS-PNETs. We identified several genes 
with known roles in neural cancer not previously implicated in CNS-PNET, including Setd2, 
Ambra1, and Usp9x(37-39). Several Ras-associated genes were mutated in our screen, including 
Nf1, Eras, Pten, and Ras3, suggesting an importance of Ras pathway activation and cooperation 
with p53 loss in PNETagenesis. Additionally, we identified NF1 loss in human CNS-PNETs. 
Activated RAS/MAPK signaling with p53 loss has been shown to drive CNS NB-FOXR2 
formation in zebrafish(40), and somatic PTEN loss is associated with human CNS-PNET(22). 
Interestingly, we did not recover any CNS-PNETs on the Pten-deficient background, possibly 
indicating that p53 loss creates a permissive cell with subsequent Ras activation.  
 FOXR2 is a member of the forkhead-box (FOX) transcription factor family, which 
contribute to a wide variety of cellular processes(41).  FOXR2 acts as an oncogene in several 
neural cancers including: malignant peripheral nerve sheath tumors, glioma, CNS-PNET, and 
medulloblastoma(6,13,34,42). Interestingly, although FOXR2 has been shown to be upregulated 
in CNS NB-FOXR2(6), we did not recover Foxr2 insertions in the SB-induced CNS-PNETs, 
including 2 tumors that resembled CNS NB-FOXR2 transcriptionally. Other insertions may 
mimic the CNS NB-FOXR2 phenotype; these 2 tumors exclusively harbored insertions in 
Epb4.1l1, Itpr1, Rbfox1, and Sphkap.  
The mechanism of FOXR2-driven tumorigenesis has proven diverse and elusive. FOXR2 
can promote WNT signaling, activate SHH signaling, promote EMT, and affect cell cycle 
(34,42-45). We examined each of these pathways in C17.2 cells and found no effect of FOXR2 
on B-catenin localization, Axin2, Gli1, p21, or CyclinD1 mRNA expression, or N-Cadherin, E-
Cadherin, or Vimentin protein levels (Supplementary Fig. 7A-D). We found that FOXR2 binds 
and stabilizes C-MYC. Mouse models with C-MYC-driven tumors show an addiction to C-MYC 
expression, suggesting C-MYC is a strong therapeutic target in cancer(46). However, directly 
targeting C-MYC has been difficult. Therefore, targeting C-MYC interacting proteins, such as 
FOXR2, may prove useful for cancer therapy. We also found that FOXR2 promotes activation of 
the FAK/SRC signaling pathway. FAK activation is associated with poor prognosis and drug 
resistance in a variety of cancers and targeting FAK produces deleterious off-target effects(47). 
Interestingly, co-targeting of FAK and C-MYC was recently shown to have synergistic effects in 
ovarian cancer(48). The ability of FOXR2 to activate both of these pathways makes it an 
excellent candidate for targeted therapy. Additionally, FOXR2 has minimal expression in adult 
tissues, making off-target toxicity risk low(13). 
 We identified ARHGAP36 as both a mouse and human medulloblastoma oncogene. 
ARHGAP36 expression in C17.2 cells promoted anchorage independent growth, tumor 
formation, leptomeningeal spread, and SHH activation. Current therapies targeting an upstream 
pathway member, Smoothened (SMO), have been met with resistance through SMO 
mutations(49). Since its interactions with PKA and SUFU are both downstream of SMO, 
ARHGAP36 poses a good target for treatment-resistant, SHH-driven medulloblastoma(17,27). 
Additionally, Arhgap36 was the most up-regulated gene in mouse allografts propagated in the 
presence of a SMO antagonist(17). Interestingly, Arhgap36 insertions occurred in mouse Shh 
and group 3/4 tumors, and ARHGAP36 is expressed across all subgroups of human 
medulloblastoma, indicating ARHGAP36 may also have non-SHH pro-tumorigenic effects.  
We identified several candidate driver genes in medulloblastoma and CNS-PNET 
relevant to human cancer. To our knowledge, this is the first study to present a genetically-
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induced CNS-PNET mouse model, providing an opportunity for studying this rare and 
aggressive tumor. We also present tumors that resemble group 3/4 medulloblastoma with high 
incidence of leptomeningeal spread, again providing a needed mouse model for these tumors. 
Interestingly, these diverse tumor types were driven with the same, Nestin-driven Cre 
recombinase, indicating that the cell of origin of non-Wnt medulloblastoma and CNS-PNET is 
Nestin+ or a close descendent. We used RNA-Seq to identify CIS genes and subtype mouse SB-
induced tumors based on human expression data. Arhgap36, our top CIS gene, was shown to 
transform a mouse neuroblast line. Foxr2 was identified as a proto-oncogene and shown to 
promote C-MYC stability and FAK pathway activation. Both of these genes offer promise as 
novel therapeutic targets in human medulloblastoma and warrant additional study. Further 
functional testing of additional CIS genes may reveal additional treatment options for embryonal 
tumors.  
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Figure 1.  
SB-induced medulloblastoma and CNS-PNET resemble human tumors.  
A, Macroscopic images of normal brain and brains with SB-induced cerebellar medulloblastoma and CNS-PNET in 
the cerebral cortex and olfactory bulbs. T=tumor. B, Medulloblastoma and CNS-PNET frequency across genetic 
backgrounds. C, Upper panels: medulloblastoma H&E. i, Rosettes (arrows), mitotic nuclei (arrowheads). Primary 
medulloblastoma (T) with leptomeningeal spread (LS). Lower panels: medulloblastoma IHC. D, Upper panels: 
CNS-PNET H&E. Cerebral cortex (ctx), hippocampal formation (hpf), dentate gyrus (dg). Inset: CNS-PNET sagittal 
section, olfactory bulb (arrow). ii, Bulk tumor with rosette formations (arrows) and mitotic nuclei (arrowheads). iii, 
Tumor cell parenchyma infiltration. Lower panels: CNS-PNET IHC. Scale bars = 50 m. 
 
Figure 2. 
SB-induced tumors resemble human medulloblastoma and CNS-PNET transcriptionally. 
A, Hierarchical clustering of medulloblastoma transcription profiles(6). Red and green boxes denote transcripts in 
SHH and group 3/4, respectively (P-value <0.002, Fisher’s Exact Test (FET)). SHH, WNT, and group 3/4 
designation indicated with red, black, and green toebars, respectively. B, Hierarchical clustering of CNS-PNET 
transcription profiles(6).  Blue boxes denote transcripts in CNS NB-FOXR2 (P-value <1.0e-8, FET). CNS NB-
FOXR2 and non-FOXR2 CNS-PNET designation are shown with blue and black toebars, respectively. Log-
transformed and mean-centered data with variance >0.5 for murine RNA-Seq datasets and >2.0 for human array 
datasets were clustered using average linkage clustering. Clusters systematically identified with node correlation 
>0.2. 
 
Figure 3. 
CIS gene identification and expression analysis in mouse and human tumors. 
A, Medulloblastoma (MB) and CNS-PNET CIS genes. B, RNA-Seq expression levels in SB-induced tumors 
(Student t test, two-tailed). C-E, Expression of CIS genes with highest variability in mouse tumors(C), human 
medulloblastoma(5)(D), and human CNS-PNET(5)(E). Log-transformed and mean-centered data with variance >1.0 
were clustered using average linkage clustering. Multiple human probes corresponding to CIS were averaged to 
obtain a single value.   
 
Figure 4. 
Increased Arhgap36 expression is associated with medulloblastoma. 
A, Arhgap36 locus with transposon insertions (green arrowheads). B, Arhgap36 expression by RNA-Seq in SB-
induced medulloblastomas (Student t test, two-tailed). C, Arhgap36 IHC in SB-induced medulloblastoma. Primary 
tumor (*), leptomeningeal spread (arrowhead). Nuclear expression in control tumor (arrow) compared to normal 
granule neural cells (inset). D, Combined TMAs analyzed for ARHGAP36 by IHC. E, ARHGAP36 positivity by 
IHC across subgrouped Johns Hopkins TMA. F, Kaplan-Meier analysis of patients from Johns Hopkins TMA (Log 
rank Mantel-Cox test). Scale bars = 50mm. 
 
Figure 5.  
ARHGAP36 and Megf10 promote tumorigenesis.  
A, Soft agar assay comparing C17.2 Luc and C17.2 ARHGAP36 (Student t test, two-tailed). B, Flank tumor volume 
of NU/J mice injected with C17.2 Luc or C17.2 ARHGAP36 (N=5, Sidak’s multiple comparisons test). C, Survival 
of NU/J mice injected intracranially with C17.2 Luc or C17.2 ARHGAP36 (N=7, Log rank Mantel-Cox test). D, 
IHC showing cerebellar and cerebral location of GFP+ C17.2 Luc or C17.2 ARHGAP36 injected into NU/J mice. E, 
Tritiated thymidine (3H-Td) incorporation assay in transduced GNPs (N=3, Benjamini, Krieger, and Yekutieli 
multiple comparisons test). F, Upper panel: qRT-PCR for Gli1 in C17.2 Luc and C17.2 ARHGAP36 (Sidak’s 
multiple comparison’s test). Gli1 expression is normalized to Gapdh. Lower panel: RNA-Seq of SB-induced 
medulloblastomas showing expression of indicated genes. G, MTS assay of C17.2 Luc and C17.2 Megf10 (Sidak’s 
multiple comparisons test). H, Soft agar assay of C17.2 Luc and C17.2 Megf10 (Student t test, two-tailed). I, Flank 
tumor volume of NU/J mice injected with C17.2 Luc (N=7) or C17.2 Megf10 (N=8)(Sidak’s multiple comparisons 
test). Error bars, SEM. Scale bars = 100mm. 
 
Figure 6. 
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16 
FOXR2 promotes transformation in human and mouse cells.  
A, Transposon insertions (green arrowheads) in the Foxr2 locus. B, Foxr2 expression by RNA-Seq in SB-induced 
medulloblastoma (Student t test, two-tailed). C, Western blot showing FOXR2 expression in C17.2 Luc and C17.2 
FOXR2. D, Soft agar assay comparing C17.2 Luc and C17.2 FOXR2 (Student t test, two-tailed). E, Wound closure 
rate of C17.2 Luc (N=14) and C17.2 FOXR2 (N=15)(Student t test, two-tailed). F, Flank tumor volume of NU/J 
mice injected with C17.2 Luc (N=7), C17.2 FOXR2MYC (N=6) or C17.2 FOXR2 (N=8)(Sidak’s multiple 
comparison’s test). G, Whole and halved brains from NU/J mice injected intracranially with C17.2 FOXR2. Scale 
bars = 1 cm. H, Survival of NU/J mice injected intracranially with C17.2 Luc (N=7) or C17.2 FOXR2 (N=10)(Log 
rank Mantel-Cox test). I, Survival of NRG mice injected intracranially with C17.2 Luc or C17.2 FOXR2 
(N=13)(Log rank Mantel-Cox test). J, Western blot of Daoy WT, Daoy #21 (FOXR2 KO), Daoy #21+ (FOXR2 KO 
with rescue FOXR2 cDNA), and Daoy #22 (has integrated CRISPR/Cas9 vector but no FOXR2 mutation). K, MTS 
assay of Daoy WT, Daoy #21, Daoy #21+ and Daoy #22 (Dunnett’s multiple comparison’s test). L, Soft agar assay 
of Daoy WT, Daoy #21, Daoy #21+ and Daoy #22 (Dunnett’s multiple comparison’s test). Error bars, SEM. 
 
Figure 7.  
FOXR2 interacts with C-MYC and N-MYC and activates FAK/SRC signaling. 
A, CoIP of endogenous C-MYC with flag-tagged FOXR2 in HSC1. B, CoIP of V5-tagged C-MYC, L-MYC and 
N-MYC with flag-tagged FOXR2 in HEK293T. C, Western blot showing cycloheximide (CHX)-treated HSC1 and 
C17.2 with and without FOXR2. CHX treatment (100 ug/ml in DMSO) was done for time indicated. D, Upper 
panel: putative FOXR2 protein domains. Lower panel: soft agar assay of C17.2 Luc or indicated FOXR2 deletion 
mutants. Error bars, SEM. E, Western blot showing effects of FOXR2 expression changes on FAK/SRC signaling.  
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